2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Silencing Ubc9 expression suppresses osteosarcoma tumorigenesis and enhances chemosensitivity to HSV-TK/GCV by regulating connexin 43 SUMOylation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The ability of herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) systems to kill tumor cells is partially dependent on the integrity of gap junction intercellular communication (GJIC) of targeted tumor cells. Recent studies have suggested that connexin 43 (Cx43), which serves a role in gap junction-mediated intercellular communication, is regulated by small ubiquitin-like modifiers (SUMOs). However, the roles of these post-translational modifications remain to be elucidated. The present study demonstrated overexpression of SUMO‑conjugating enzyme Ubc9 (Ubc9) protein in osteosarcoma. Silencing Ubc9 by siRNA inhibited osteosarcoma cell proliferation and migration, and significantly increased the sensitivity of cells to HSV-TK/GCV systems both in vitro and in vivo. Further experimentation demonstrated that silencing Ubc9 induced decoupling of SUMO1 from Cx43, generating increased free Cx43 levels, which is important for reconstructing GJIC and recovering cellular functions. In conclusion, the present study revealed a novel method for the effective restoration of GJIC in osteosarcoma cells, which may increase their sensitivity to conventional chemotherapy.

          Related collections

          Author and article information

          Journal
          Int J Oncol
          International journal of oncology
          Spandidos Publications
          1791-2423
          1019-6439
          Sep 2018
          : 53
          : 3
          Affiliations
          [1 ] Department of Trauma and Orthopedics, Beijing University People's Hospital, Beijing 100044, P.R. China.
          [2 ] Department of Orthopedics, The Fifth Central Hospital of Tianjin, Tianjin 300450, P.R. China.
          [3 ] Central Laboratory, The Fifth Central Hospital of Tianjin, Tianjin 300450, P.R. China.
          [4 ] Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
          [5 ] Department of General Surgery, Beijing University First Hospital, Beijing 100034, P.R. China.
          Article
          10.3892/ijo.2018.4448
          29956745
          882a360e-1689-41df-8610-e33a1dbbaa9e
          History

          Comments

          Comment on this article